Medical Device Branding: How to Build a Brand Clinicians, Buyers and Investors Trust (EU/MDR Edition)

A surgeon flicks through your brochure between two cases. A procurement lead opens your website to find the CE certificate. An investor scrolls your LinkedIn page before the second meeting. Each of them decides, in a few minutes, whether your device belongs to a clinical partner or to one more vendor.

Medical device branding decides which way that goes. It covers four things: the position you hold, the words you use, the way you look and the evidence behind every claim. In medtech branding, all four sit inside a regulatory envelope.

Your intended use limits what the brand can promise. Your label limits how small the logo can go. Your CE marking decides which devices you can promote in Europe, and from when.

The sections below follow the order in which that envelope bites: what you can claim, what you can call the device, what you can show and when. Most of the expensive mistakes in device branding are order mistakes, not design mistakes.

Ooho, a life sciences branding agency in Leuven, wrote this guide for European device companies. It draws on Ooho's medtech projects.

What is medical device branding?

Medical device branding is the system a device company uses to be known for one thing by clinicians, buyers and investors. It has four parts: positioning, verbal identity, visual system and evidence. The logo is the smallest of the four. In medtech, evidence earns the place on the shortlist: clinicians check it before they believe anything else.

Unlike wider medical branding, a device brand also lives on the product: its label and its instructions for use (IFU). That changes the test for every part of the system.

Positioning is the part founders skip and the part the market remembers. Spentys, an orthotics start-up, began with no brand recognition. A few years of conferences, LinkedIn content and a consistent identity later, prospects already knew it as "the 3D guys". That phrase is the brand. The booth, the website and the cold emails existed to make it stick. If your prospects cannot repeat one phrase about you, the rest of the system has nothing to carry. Decide the phrase first.

Evidence is the part most device brands underuse. Their studies sit on one "Clinical data" page, and every other page asks for trust it has not earned. Ooho's advice to a medtech company that wants hospitals to see it as a clinical partner was to make the evidence the brand. The same advice went to a lung-imaging device company: put the studies on its website, brochures and distributor decks. The cost of one buried page is a clinician who reads your claim and finds nothing behind it.

Even chart style is part of the brand. Set one style for every chart and annotation in a device brochure. Clinicians read numbers fast, and consistent details make the same data look more credible.

Why are medtech brands harder to build?

Medtech brands are harder because one device has several buyers, and each needs a different reason to believe. A surgeon wants clinical proof, a procurement lead wants total cost and an investor wants a return. Every message stays inside the device's intended use, and most buyers check you online before the first meeting.

Forrester found that 92% of business buyers start a purchase with at least one supplier in mind, and 43% of European buyers start with one preferred supplier. Its 2024 study of business buying counts an average of 13 people in each purchase decision. In a hospital, that group can span clinicians, nurses, procurement and finance. The shortlist forms before you know you are on it.

Start with the audience map: what each person needs to believe, and where they check.

When one device serves several clinical applications, map the audience per application, then per job title. Spentys split its messages even inside one specialty. Surgeons and orthotic technicians each got their own version, because the two professions judge the same device on different grounds. One message for both means one of them reads a message written for someone else.

Distributors raise the stakes. When a distributor's rep mentions a device, the clinician looks it up and expects a clear story. The lung-imaging company's team counts a physician who arrives already convinced as half the sale. Its distributor runs the demos and the selling. So the brand has to equip reps who never sat in a strategy meeting, and it has to do the convincing before the rep walks in.

That lookup increasingly runs through AI. In the AMA's 2026 survey of 1,692 US physicians, 81% used AI at work, up from 38% in 2023. Summarising research and standards of care was the most common use. Publish your evidence on plain, well-structured pages, so those tools find the study and quote the intended use correctly. A page those tools misread repeats a claim you never made.

Procurement runs a different test. EU law lets hospitals award tenders on quality, life-cycle cost and after-sales service, not just price (Directive 2014/24/EU, Article 67). In practice, MedTech Europe reports that 61.8% of public medtech tenders are awarded on price alone, against 51.8% across all sectors. Evidence earns your place on the shortlist. Total cost decides most tenders. Write for both, or you win the clinician and lose the committee.

The same visual reads differently to each audience. A skin-imaging device company rejected a dark creative route because it suited investor events but put distance between the practitioner, the patient and the device. That route would also have split doctor and patient communication into two tracks. The company chose one route every audience could read.

Write so the clinician stays in charge. Two Ooho clients rewrote messages that implied their product took over the clinician's role. The versions that worked framed the product as a tool for the clinician's decision. A clinician who feels replaced stops reading.

Branding inside the regulatory envelope

Regulation decides what a medtech brand can say, where and when. The intended use caps every claim, trademark law decides which names survive, and the device label fixes some brand elements for years. Plan all three with your regulatory colleagues before design starts. Change them after launch and you pay in relabelling, new review rounds or a CE marking update.

MDR Article 7 bans text, names, trademarks and pictures that mislead users or patients about a device's intended purpose (the MDR's term for intended use), safety or performance. The ban covers labelling, instructions for use and advertising, and IVDR Article 7 applies it to diagnostics. It reaches your website and your booth, not just your label.

Changes after certification are common: 9,724 of the 32,898 MDR applications lodged by 28 February 2026 were for changes to existing certificates (European Commission notified body survey). New certificates take time, and 51% of notified bodies need 13 to 18 months to issue one covering both quality system and product. Any brand element that waits on that clock waits a year or more.

Claims follow the intended use

A diagnostics software company preparing for IVDR certification put it in four words: "We can't sell promises." The rule reaches further than most teams expect. At US congresses, even a roll-up banner cannot claim an analysis the product is not cleared for. That is why Ooho writes validated claims into the messaging playbook, then reviews every key term with the client in two or three sessions. The review sounds slow. It is faster than taking down a banner on the congress floor.

Evidence placement follows the same rule. A skin-imaging device company presents its indications as current clinical use, so ongoing studies sit on the About page, away from product pages. A reader on the product page sees only what the device is cleared to do. A cleared digital health client worked through the same logic. It built a key message on being a regulated option. It then tested a line tying its clearance to gynaecologist use, judged the line not credible and dropped it. Your clearance is a fact. How far you stretch it is a choice, and reviewers notice the stretch.

Review capacity sets the pace. An early-stage diagnostics company had no IFU and no approved claims, so it planned a technology page first and held the product page. Its medical lead reviews content half a day a week. At that pace, a three-to-four-week design window left no room for claims review, so the window moved. Count your reviewer's hours before you set the design schedule. A product page built on claims that later fail review costs you the page and the launch date.

Names, labels and markets

Clear the name before design sign-off. An infant-feeding device start-up sent its shortlist to its patent attorney before any logo work began. The medical root alone was descriptive and risky to protect, so the shortlisted name echoes the root without using it. A local-language check showed one candidate was crude slang in a regional language. Skip either check and you redo the name after design sign-off, with new searches in every launch market and a logo that no longer fits. Send your shortlist to the attorney and to a native speaker in each market first.

The device carries the brand too. A lung-imaging company's printed processor membrane is part of its CE-marked device, so new artwork waits for the next periodic CE marking update. Anything printed on the device moves at the pace of the certificate, not the pace of the brand. Markets add limits of their own. A US device maker planned an English-for-Europe site version for EU visitors and expected to cut promotional homepage sections first. Check UK rules separately.

EU and US constraints to plan for

Plan these points with regulatory colleagues; the table is a planning aid, not legal advice. Outside experts handle reimbursement and country-specific questions, and Ooho has done some EU regulatory work when clients asked.

Medical device brand strategy: messaging before logo

Write the messaging before anyone draws a logo. A medtech brand has to say who it serves, what it changes for them and what proof backs that, in words a regulatory reviewer accepts. Design then gives those words a form. Reverse the order and the logo ends up carrying a story nobody agreed on.

Ooho starts every brand with the message: one-to-one interviews with the client's team, then a workshop that settles the few positioning debates. The method caps a brand at three ideal customer profiles and three value pillars per segment. The cap is the point. A brand with nine pillars has none.

Fewer messages win. The skin-imaging device company cut more than 55 proof points to between three and five. Rank what stays by strength, not popularity. The cleared digital health client kept a benefit its users like but moved it lower in its message hierarchy, because a popular benefit is not the same as a decisive one.

Key messages are not ad copy. They brief the creative team, the sales deck and the website, so test them on real pages. When the second playbook draft is about 80% validated, Ooho writes the website, and the pages surface two or three final changes. A message that survives the playbook and fails on the page was never finished.

Messaging can start before claims are final. A diagnostics company still in development began its website on its current positioning narrative, not a finished messaging map. You do not have to wait for the last claim to clear before you write. You do have to know which lines will change.

Visual identity that reads clinical-grade without looking sterile

A clinical-grade identity earns trust through order, not through the colour blue. Use white space, a restrained palette and type that stays legible on a label, then add one distinctive colour and a human detail. Sterile brands copy the category; clinical-grade brands follow clear rules and still look like themselves.

Large medtech brands serve so many stakeholders that they average to the middle. The result is polished and forgettable. A challenger that copies it inherits the forgettable part without the market share.

Blue is the default for the same reason. In four experiments, people rated blue brands as more competent (Labrecque and Milne, 2012). When every competitor buys the same reassurance, it stops setting anyone apart.

The infant-feeding start-up's founder first asked for blue because medical devices use it. The better route was to stand out from the sea of blue: white packaging and clean type carry the trust, while brand accents carry the difference. The founder agreed that the category colour works against differentiation. If your brief says "medical, so blue", ask what else is carrying the trust. White space and type can carry it.

Write the brief as paired tensions. The same project asked for clinical but not cold, premium but not excessive, scientific but not intimidating. Each pair names the risk on both sides, so every design review has a test. Without the pairs, a review comes down to taste, and taste changes with the room.

White space does the clinical work. Reviewing a lung-imaging company's brand, Ooho flagged two assets to keep: the white space most companies fill and the rounded shapes that make it approachable. Before you add anything to a device brand, check what is already doing the work.

Case study: building a new-category brand for Sonovein

Sonovein shows how a device brand earns a premium position in a category buyers have never seen. Ooho wrote its brand narrative around three ideas: safety, innovation and a patient-first experience. The work covered brand development, web design, imagery and video, slide decks and social media templates.

Sonovein is Theraclion's non-invasive treatment for varicose veins, guided by robotic ultrasound. The old brand opened with photos of bare legs and sea water, and a blue banner listed what the treatment avoids: catheters, chemical injections and incisions. The robot itself appeared once, as a small cut-out beside that list. The brand sold the absence of other treatments, not the presence of its own.

The new brand puts the robot at the centre. A product shoot sets it against black, and line illustrations redraw it in outline beside a matching set of line icons. The system runs in two modes: dark for the website and event banners, light for the website and slide decks.

The lesson for a new category: when buyers have nothing to compare, show the technology first and keep every touchpoint in one visual system. A new category without a visible object is a claim the buyer cannot picture.

Case study: from tech start-up to medtech brand with Spentys

Spentys went from an unknown 3D-printing start-up to the company large orthotics and prosthetics (O&P) firms treat as the thought leader in 3D production. Three moves did it: a narrower market, a visual brand borrowed from software marketing, and messaging reviewed every six months as the company grew.

Spentys first sold to hospitals, where 3D printing proved too slow and too costly for the casting room. It moved to custom long-term orthotics for the O&P market. The visual brand took its cues from software companies, with a conversion-led website, strong product photography and video. The narrower market made the sharper brand possible.

The team reviews the messaging every six months and updates the website and brochures to match. When Spentys left the hospital market, its hospital-era blog posts came down too. That keeps AI search answers on the current positioning, instead of quoting a market the company left. Today Spentys positions itself as the automation infrastructure for digital O&P production. A brand that outgrows its old content has to remove it, not just stop writing it.

Rebrand or refresh? Signals for medtech companies

Refresh when people already recognise your logo and colour but your materials have drifted apart. Rebrand when the company itself has changed: a new market, a new product line or partners who must sell under your name. In a refresh, keep what clinicians recognise and evolve the rest.

Investors draw the same line. A study of corporate name changes found that markets rewarded a new name most at industrial firms and underperforming ones (Horsky and Swyngedouw, 1987). They read it as a signal that the business itself would change. A rebrand without that change is a cost with no signal attached.

In an audit for the lung-imaging company, some pieces had rounded corners and others gradient circles. Each piece looked fine on its own. Next to each other, they looked like three companies. A strong brand shows the same structure on every piece. The plan keeps the logo, colour and white space, and adds a graphic language only that company uses. If your sales team has to explain which brochure is the current one, you are already paying for the drift.

How to choose a medical device branding agency

Choose a medtech branding agency that audits your brand before it designs, names who does the work and hands over every source file. Ask to see its device or diagnostics work under MDR or IVDR, and ask where its regulatory knowledge stops. Then name one person on your side who owns marketing.

Start with the audit. A good agency runs one before any creative work, so both sides agree on the problem and nobody reviews designs they never asked for. After the lung-imaging audit, the client said the diagnosis matched its own view of the brand. That agreement is what you are buying. Designs reviewed without it get judged on taste.

Then check the handover, and ask which work stays in-house and which goes to freelancers. A complete handover includes the master files, clean versions without graphics and every graphic element as a separate file. Anything less means you come back to the agency for every new slide.

Last, keep one owner on your side. Agency work slows when every decision waits for a founder or CEO.

Checklist: 12 questions to pressure-test a medtech brand

Pressure-test a medtech brand on claims, audiences and daily use. Check that every claim matches the intended use, that each audience finds its own message and that your team applies the brand without the agency. Run these 12 questions before a launch, a congress or a new market, and fix every "no" first.

Every section of this guide comes back to one order of operations: clear the claims, the name and the label constraints with your regulatory colleagues, then write the messages, then let design give them a form. Each step you skip returns later as a relabel, a new review round or a congress banner you cannot show. Do the slow work first, and the brand is ready on the day you can sell.

Medical device branding FAQ

Most medtech branding questions come down to five rules. Build the brand before approval, keep every claim inside the intended use and write one message per audience. Rebrand only when the company itself has changed, and choose an agency that audits before it designs.

What is medical device branding?

Medical device branding is the system a device company uses to be known for one thing by clinicians, buyers and investors. It has four parts: positioning, verbal identity, visual system and evidence. Evidence earns a place on the shortlist because clinicians check it first.

Can you brand a medical device before CE marking or FDA clearance?

Yes: build the positioning, name and visual system before approval, so the brand is ready on the first day you can sell. Promotion waits: in the EU, show the device at fairs only with a visible demonstration-only sign and make no sales. In the US, make no safety or effectiveness claims for an investigational device.

What can a medical device brand claim?

A brand can claim only what the device's approval covers. In the EU, that ceiling is the intended purpose in your technical documentation, and Article 7 of the MDR and IVDR bans misleading claims and names. In the US, it is the indications for use in your 510(k), De Novo or PMA decision.

Who does a medtech brand need to convince?

Four groups: clinicians, procurement and value committees, investors and, for some devices, patients. Each group makes a different decision on different evidence. Write one message per decision, and keep the same positioning, name and visual system across all four groups.

Should a medtech company rebrand or refresh?

Refresh when people already recognise your logo and colour but your materials have drifted apart. Rebrand when the company itself has changed: a new market, a new product line or partners who must sell under your name. In a refresh, keep what clinicians recognise and evolve the rest.

What should you look for in a medical device branding agency?

Look for an agency that audits before it designs, shows device or diagnostics work under MDR or IVDR and says where its regulatory knowledge stops. Then ask who does the work, which parts go to freelancers and whether you receive every source file.

From CE mark to first sale

A CE mark lets you sell in Europe, but it does not make a single hospital buy. Join MArS and Ooho on 28 October 2026 at 17:00 CET for the webinar "From CE Mark to First Sale?" The session covers the steps between certification and the first purchase order. Register now, and bring the launch plan you want to pressure-test.

Sources

• European Commission study (GÖG, Areté, Civic Consulting), 20th notified body survey, data to 28 February 2026, published 2 July 2026
• Regulation (EU) 2017/745 on medical devices (MDR), Articles 7 and 21(3)
• Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), Article 7
• 21 CFR 812.7, prohibition of promotion of investigational devices
• Directive 2014/24/EU on public procurement, Article 67
• MedTech Europe, Buying European is not enough: Europe must buy better, 3 June 2026
• Forrester, B2B Marketing And Sales Are Too Late To Influence Decisive Buyers, 2025, based on the 2024 Buyers' Journey Survey
• Forrester, The State Of Business Buying, 2024, press release, 4 December 2024
• American Medical Association, 2026 Physician Survey on Augmented Intelligence, March 2026
• Labrecque and Milne, Exciting red and competent blue: the importance of color in marketing, Journal of the Academy of Marketing Science, 2012
• Horsky and Swyngedouw, Does it pay to change your company's name? A stock market perspective, Marketing Science, 1987

Client examples without a public case study are anonymised.